【レポートの概要（一部）】
1. Report Overview
1.1 Global Ophthalmic Drugs: Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Ophthalmic Treatments – An Industry Overview
2.2 The Human Eyes – Structurally Delicate And Functionally Intricate Organs
2.3 The Global Burden Of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: A Major Cause Of Vision Loss
2.5.1 A Classification Of Glaucoma
2.5.1.1 Primary Open-Angle Glaucoma
2.5.1.2 Acute Angle-Closure Glaucoma
2.5.1.3 Congenital Glaucoma
2.5.1.4 Secondary Glaucoma
2.5.1.5 Normal-Tension Glaucoma
2.5.1.6 Ocular Hypertension
2.5.2 Risk Factors For Glaucoma
2.5.3 Diagnosis Of Glaucoma
2.5.4 Drug Treatment Of Glaucoma
2.5.5 Laser Treatment And Surgery For Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors For AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis Of Diabetic Retinopathy
2.7.2 Treatment Of Diabetic Retinopathy
2.8 Ocular Allergy And Allergic Conjunctivitis
2.8.1 Diagnosis Of Ocular Allergy
2.8.2 Treatment Of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Treatment Of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment Of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome
2.12 Phases of Clinical Trials
2.13 Ophthalmic Drugs: Market Definition In This Report
3. The Global Ophthalmic Drugs Market, 2016-2026
3.1 The Global Ophthalmic Drugs Market: Market Overview
3.2 Categorisation of the Global Ophthalmic Drugs Market
3.3 The Global Ophthalmic Drugs Market In 2015
3.4 The Global Ophthalmic Drugs Market: Market Forecast 2016-2026
3.5 Ophthalmic Drugs: Changing Market Shares by Sector 2016-2026
4. The Retinal Disorder Drugs Market: Market Analysis and Forecast 2016-2026
4.1 Leading Products in the Retinal Disorder Drugs Market, 2015
4.2 Retinal Disorders: Market Trends And Developments, 2016
4.2.1 The Rise And Rise Of Eylea
4.2.2 The Debate Around Off-Label Avastin Use And The Role Of Novartis And Roche
4.2.3 How Likely Is Avastin’s Expansion Into Age-Related Macular Degeneration?
4.2.4 Jetrea: Underwhelming Sales Cause ThromboGenics to Switch Focus to Their Pipeline
4.2.5 Drug/Device Combination Products Entering The Market
4.2.6 Does Regenerative Medicine Have A Successful Future In Ophthalmics?
4.3 Retinal Disorder Drugs: Market Forecast 2016-2026
4.3.1 Retinal Disorder Drugs: Changing Market Shares By Leading Drugs 2016-2026
4.4 Leading Drugs For The Treatment Of Retinal Disorders
4.5 Eylea (aflibercept) – Regeneron/ Bayer/ Santen
4.5.1 Recent Approvals For Eylea
4.5.2 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.5.3 Eylea: Sales Forecast 2016-2026
4.5.4 Possible Combination Therapies Involving Eylea
4.6 Lucentis (ranibizumab) – Roche/ Novartis
4.6.1 Lucentis: Sales Forecast 2016-2026
4.6.2 Less Frequent Dosing Approved In US For Lucentis
4.6.3 New Indications For Lucentis
4.6.4 Possible Combination Therapy Involving Lucentis
4.7 Avastin (bevacizumab) – Roche
4.7.1 Avastin: Sales Forecast 2016-2026
4.7.2 Compounding Pharmacies And Safety Risks
4.8 Visudyne (verteporfin) – Valeant/ Novartis
4.8.1 Visudyne: Sales Forecast 2016-2026
4.9 Jetrea (ocriplasmin) – ThromboGenics/ Novartis
4.9.1 Jetrea: Recent Sales Performance
4.9.2 Clinical Study Plans For Jetrea
4.9.3 Jetrea: Sales Forecast 2016-2026
4.9.4 Possible Acquisition Move On ThromboGenics
4.9.5 R&D Agreements With Eleven Biotherapeutics and Bicycle Therapeutics
4.10 Other Retinal Disorder Drugs
4.10.1 Iluvien (fluocinolone implant) – Alimera Sciences
4.10.2 Ozurdex (dexamethasone implant) – Allergan
4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2016-2026
5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis And Forecast 2016-2026
5.1 Leading Products In The Allergic, Inflammatory And Infective Drugs Market, 2015
5.2 Allergic, Inflammatory And Infective Drugs: Market Trends And Developments, 2016
5.2.1 The Growth Prospects For Allergic, Inflammatory And Infective Drugs
5.2.2 Topical NSAIDs Launched: Prolensa and Ilevro
5.3 Allergic, Inflammatory And Infective Drugs: Market Forecast 2016-2026
5.3.1 Allergic, Inflammatory And Infective Drugs: Changing Market Shares By Leading Drugs 2016-2026
5.4 Leading Drugs For The Treatment Of Allergic, Inflammatory And Infective Ophthalmic Conditions
5.5 Patanol And Pataday (olopatadine) – Alcon (Novartis)
5.5.1 Pataday: Sales Forecast 2016-2026
5.5.2 Impending Generic Competition For Patanol And Pataday
5.5.3 Approval Of Pazeo Solution
5.5.4 Patanol: Sales Forecast 2016-2026
5.6 Vigamox (moxifloxacin) – Alcon (Novartis)
5.6.1 Intensifying Competition And Generics Drug Challenge To Vigamox
5.6.2 Moxeza: A Next-Generation Form of Vigamox
5.6.3 Vigamox: Sales Forecast 2016-2026
5.7 TobraDex (tobramycin/dexamethasone) – Alcon (Novartis)
5.7.1 The Development And Commercialisation Of TobraDex ST
5.7.2 TobraDex: Sales Forecast 2016-2026
5.8 Cravit (levofloxacin) – Santen
5.8.1 Cravit: Sales Forecast 2016-2026
5.9 Acular (ketorolac) – Allergan (Actavis)
5.9.1 5.9.1 Acular: Sales Forecast 2016-2026
5.10 AzaSite (azithromycin) – Akorn
5.10.1 AzaSite: Sales Forecast 2016-2026
5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast 2016-2026
6. Glaucoma Drugs Market: Market Analysis And Forecast 2016-2026
6.1 Glaucoma Drugs: Market Overview
6.1.1 Leading Products In The Glaucoma Drugs Market, 2015
6.2 Glaucoma Drugs: Market Trends And Developments, 2016
6.2.1 Patent Expiration: A Major Restraint For Glaucoma Drugs
6.2.2 Preservative-Free Formulation Trends
6.2.3 Innovation In Treatments For Glaucoma
6.3 Simbrinza: First Beta-Blocker-Free Combination
6.4 Glaucoma Drugs: Market Forecast 2016-2026
6.4.1 Glaucoma Drugs: Changing Market Shares By Leading Drugs 2016-2026
6.5 Leading Drugs For The Treatment Of Glaucoma
6.6 Lumigan And Ganfort (bimatoprost) – Allergan (Actavis)
6.6.1 Lumigan And Ganfort: Sales Forecast 2016-2026
6.7 Xalatan And Xalacom (latanoprost) – Pfizer
6.7.1 Xalatan/Xalacom: Sales Forecast 2016-2026
6.8 Travatan/Travatan Z And DuoTrav (travoprost) – Novartis
6.8.1 Travatan/Travatan Z And DuoTrav: Sales Forecast 2016-2026
6.9 Alphagan/Alphagan P And Combigan (brimonidine) – Allergan
6.9.1 Alphagan/Alphagan P And Combigan: Sales Forecast 2016-2026
6.10 Trusopt And Cosopt/Cosopt PF (dorzolamide) – Merck/ Santen
6.10.1 Divestment Agreement With Santen And Akorn
6.10.2 Trusopt: Sales Forecast 2016-2026
6.10.3 Cosopt And Cosopt PF: Sales Forecast 2016-2026
6.11 Azopt (brinzolamide) – Novartis
6.11.1 Azopt: Sales Forecast 2016-2026
6.12 Tapros (tafluprost) – Santen
6.12.1 Tapros: Sales Forecast 2016-2026
6.13 Zioptan (tafluprost) – Akorn
6.13.1 Zioptan: Sales Forecast 2016-2026
6.14 Other Glaucoma Drugs: Sales Forecast 2016-2026
7. Dry Eye Drugs Market: Market Analysis And Forecast 2016-2026
7.1 Dry Eye Drugs: Market Overview
7.1.1 Leading Products In The Dry Eye Drugs Market, 2015
7.2 Dry Eye Drugs: Market Trends And Developments, 2016
7.2.1 Restasis: Patent Elongations And Generic Challenges Creating Uncertainty
7.2.2 Intensifying Research Focused On Dry Eye
7.2.3 Improving Diagnostic Tools
7.3 Dry Eye Drugs: Market Forecast 2016-2026
7.3.1 Dry Eye Drugs: Changing Market Shares By Leading Drugs 2016-2026
7.4 Leading Drugs For The Treatment Of Dry Eye
7.5 Restasis (ciclosporin) – Allergan (Actavis)
7.5.1 Restasis – Generic launch in 2016?
7.5.2 Restasis: Sales Forecast 2016-2026
7.6 Refresh Brand Products – Allergan (Actavis)
7.6.1 Refresh Brand Products: Sales Forecast 2016-2026
7.7 Hyalein (hyaluronic acid) – Santen
7.7.1 Hyalein: Sales Forecast 2016-2026
7.8 Diquas (diaquafosol) – Santen
7.8.1 Diquas: Sales Forecast 2016-2026
7.9 Other Dry Eye Drugs: Sales Forecast 2016-2026
7.10 Other Ophthalmic Drugs
7.10.1 Hetlioz (tasimelteon) – Vanda Pharmaceuticals
7.10.2 Hetlioz: Sales Forecast 2016-2026
8. Leading National Markets For Ophthalmic Drugs, 2016-2026
8.1 The Ophthalmic Drugs Market By Region
8.1.1 The Global Distribution Of Ophthalmic Drugs In 2015
8.2 Leading National Markets: Forecast 2016-2026
8.2.1 Changing Market Shares By Region, 2016-2026
8.3 Regional Ophthalmic Drugs Markets: Analysis And Forecasts, 2016-2026
8.4 United States: The Largest Ophthalmic Drugs Market
8.4.1 How Will The Rise Of A Biosimilars Market Impact On US Ophthalmic Drugs?
8.4.2 US Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5 EU5
8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2016-2026
8.5.2 Germany
8.5.2.1 German Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5.3 France
8.5.3.1 French Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5.4 UK
8.5.4.1 UK Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5.4.2 Brexit – Increased Uncertainty May Affect the UK Ophthalmic Drug Market
8.5.5 Italy
8.5.5.1 Italian Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5.6 Spain
8.5.6.1 Spanish Ophthalmic Drugs Market: Market Forecast 2016-2026
8.6 Japan
8.6.1 The Cost Of Treatment In Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Ophthalmic Drugs Market Forecast 2016-2026
8.7 8.7 China
8.7.1 Expansion Of Healthcare Coverage and Reimbursement in China
8.7.2 Price Controls And The Anhui Model
8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2016-2026
8.8 Brazil
8.8.1 How Will Brazil’s Growing Healthcare Influence Ophthalmic Drugs
8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2016-2026
8.9 Russia
8.9.1 How Will Russia’s Economic Status Affect Its Pharma Industry?
8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2016-2026
8.10 India
8.10.1 The Impact Of The Drug Prices Control Order On Indian Pharma
8.10.2 India’s Expansion Of Healthcare Provision
8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2016-2026
8.11 Rest of the World
8.11.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2016-2026
9. Leading Companies in the Ophthalmic Drugs Market, 2016-2026
9.1 Ophthalmic Drugs – A Changing Market Landscape
9.2 Leading Companies In The Ophthalmic Drugs Market, 2015
9.2.1 Ophthalmic Drugs Market: Leading Companies Forecast 2016-2026
9.2.2 Ophthalmic Drugs: Changing Market Shares By Leading Companies 2016-2026
9.3 Novartis (Alcon)
9.3.1 Novartis: Ophthalmic Drugs Portfolio, 2015
9.3.2 Novartis: Sales Forecast 2016-2026
9.3.3 Novartis: Ophthalmic Drugs Development Pipeline, 2016
9.3.4 Novartis: Recent Developments
9.3.4.1 Novartis Restructures Following Strategic Review
9.3.4.2 Novartis Licenses Ophthotech’s Fovista
9.4 Regeneron
9.4.1 Regeneron: Ophthalmic Drugs Portfolio, 2015
9.4.2 Regeneron: Recent Developments
9.4.2.1 Expanding Indications For Eylea
9.4.2.2 Eylea/Zaltrap And The Davis-Smyth Patent Agreements
9.4.3 Regeneron: Sales Forecast 2016-2026
9.4.4 Regeneron: Ophthalmic Drugs Development Pipeline, 2015
9.5 Allergan (Actavis)
9.5.1 Allergan: Ophthalmic Drugs Portfolio
9.5.2 Allergan: Recent Developments
9.5.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
9.5.2.2 How Real Is The Threat Of Generic Restasis?
9.5.2.3 Valeant’s Attempted Takeover Squashed By Actavis Bid
9.5.3 Allergan: Sales Forecast 2016-2026
9.5.4 Allergan: Ophthalmic Drugs Development Pipeline, 2016
9.6 Roche
9.6.1 Roche: Ophthalmic Drugs Portfolio, 2016
9.6.1.1 Lucentis: US Sales Forecast 2016-2026
9.6.2 Roche: Sales Forecast 2016-2026
9.6.3 Roche: Ophthalmic Drugs Development Pipeline, 2016
9.7 Valeant
9.7.1 Valeant: Ophthalmic Drugs Portfolio, 2015
9.7.2 Valeant: Recent Developments
9.7.2.1 Valeant’s Acquisition of Bausch and Lomb Still Driving Its Ophthalmic Portfolio
9.7.3 Valeant: Sales Forecast 2016-2026
9.7.4 Valeant: Ophthalmic Drugs Development Pipeline, 2016
9.7.5 Valeant: Difficult End to 2015 Leads to Uncertainty About Company Future
9.8 Santen
9.8.1 Santen: Ophthalmic Drugs Portfolio, 2015
9.8.2 Santen: Recent Developments
9.8.2.1 Santen Acquires Novagali Pharma
9.8.2.2 Santen Acquires Merck’s Ophthalmic Drugs Portfolio
9.8.3 Santen: Sales Forecast 2016-2026
9.8.4 Santen: Ophthalmic Drugs Development Pipeline, 2016
9.9 Bayer
9.9.1 Bayer: Ophthalmic Drugs Portfolio
9.9.2 Bayer: Sales Forecast 2016-2026
9.10 Pfizer
9.10.1 Pfizer: Ophthalmic Drugs Portfolio, 2016
9.10.1.1 Xalatan/Xalacom – Pfizer’s Leading Ophthalmic Products
9.10.1.2 Macugen – Valeant/Pfizer
9.10.2 Pfizer: Recent Developments
9.10.2.1 Pfizer Attempts to Acquire AstraZeneca
9.10.2.2 Pfizer Attempts Merger with Allergan
9.10.3 Pfizer: Sales Forecast 2016-2026
9.10.4 Pfizer: Ophthalmic Drugs Development Pipeline, 2016
9.11 Senju
9.11.1 Senju: Ophthalmic Drugs Portfolio
9.11.2 Senju: Sales Forecast 2016-2026
9.11.3 Senju: Ophthalmic Drugs Development Pipeline, 2016
9.11.3.1 Y 39983 (SNJ 1656)
9.11.3.2 Difluprednate (SJE-2079)
10. Ophthalmic Drugs: Research And Development Pipeline, 2016-2026
10.1 The Ophthalmic Drugs Pipeline: Intensive Development Efforts In Retinal Disorders
10.2 Drugs For Retinal Disorders: Development Pipeline, 2016
10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
10.3 Retinal Disorders: Filed or Recently Launched
10.3.1 Compaq Sipp (conbercept) – Chengdu Kanghong Pharmaceutical
10.3.2 Lipidil (fenofibrate) – Abbott
10.3.3 Iluvien (fluocinolone) – Alimera Sciences
10.4 Drugs In Phase 3 Development For Retinal Disorders
10.4.1 AGN150998 And MP0260 (Anti-VEGF DARPins) – Allergan
10.4.2 Fovista and Zimura – Ophthotech Corporation
10.4.3 Lampalizumab (anti-Factor D Fab) – Roche
10.4.4 MC-1101 (hydralazine) – MacuCLEAR
10.4.5 Squalamine (anti-angiogenic drug) – OHR Pharmaceutical
10.4.6 Tandospirone (serotonin 1A agonist) – Alcon (Novartis)
10.4.7 UF-021 (unoprostone) – R-Tech Ueno
10.5 Drugs In Phase 2 Development For Retinal Disorders
10.5.1 AKB-9778 (Tie2 activator) – Aerpio Therapeutics
10.5.2 Luminate (ALG-1001; Integrin peptide therapy) – Allegro/Senju
10.5.3 AGN208397 (beclomethasone) – Allergan
10.5.4 CPC 551 – Colby Pharmaceutical
10.5.5 ESBA1008 (anti-VEGF mAb) – Alcon (Novartis)
10.5.6 iCo-007 (antisense inhibitor of C-raf kinase mRNA) – iCo Therapeutics
10.5.7 LFG316 (anti-C5 mAb) – Novartis
10.5.8 Intravitreal brimonidine implant – Allergan
10.5.9 Optina (danazol) – Ampio Pharmaceuticals
10.5.10 PF-655 (synthetic siRNA) – Quark/Pfizer
10.5.11 Premiplex (SHP-607) – Shire
10.5.12 Renexus (ciliary neurotrophic factor) – Neurotech
10.5.13 Zybrestat (fosbretabulin) – Oxigene/Symphony VIDA
10.6 Drugs In Phase 1 and Pre-clinical Development for Retinal Disorders
10.6.1 BDM-E – BioDiem
10.6.2 NADPH Oxidase Inhibitors – Alimera Sciences
10.6.3 PAN-90806 (topical VEGF inhibitor) – PanOptica
10.6.4 Plasma Kallikrein Inhibitors (KVD001) – KalVista
10.6.5 QLT091001 (synthetic retinoid) – QLT
10.7 Drugs For Allergic, Inflammatory And Infective Ophthalmic Conditions: Development Pipeline, 2016
10.8 Drugs In Phase 3 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
10.8.1 EGP-437 (dexamethasone) – EyeGate Pharmaceuticals
10.8.2 IBI-10090 and IBI-20089 – Icon Bioscience
10.8.3 KPI-121 (loteprednol etabonate) – Kala
10.9 Drugs In Phase 2 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
10.9.1 CF101 (adenosine A3 receptor agonist) – Can-Fite BioPharma and OphthaliX
10.9.2 FST-100 (povidone-iodine/dexamethasone) – Shire
10.9.3 NVC-422 (auriclosene) – NovaBay
10.9.4 Sarilumab – Regeneron
10.10 Drugs In Phase 1 And Pre-clinical Development For Allergic, Inflammatory and Infective Ophthalmic Conditions
10.10.1 Finafloxacin – MerLion Pharmaceuticals/Novartis
10.11 Drugs For Glaucoma: Development Pipeline, 2016
10.12 Drugs In Phase 2&3 Development For Glaucoma
10.12.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) – Valeant
10.12.2 AMA0076 (ROCK inhibitor) – Amakem
10.12.3 Rhopressa (AR-13324; ROCK and NET inhibitor) And Roclatan (PG324; ROCK inhibitor) – Aerie Pharmaceuticals
10.13 Drugs In Phase 1 And Pre-clinical Development For Glaucoma
10.14 Drugs For Dry Eye: Development Pipeline, 2016
10.15 Drugs In Phase 3 Development For Dry Eye
10.15.1 EBI-005 (IL-1R antagonist) – Eleven Biotherapeutics
10.15.2 Lifitegrast (integrin antagonist) – Shire
10.15.3 Tavilermide (formerly MIM-D3 tyrosine kinase receptor antagonist) – Allergan
10.15.4 SI-614 (modified hyaluronate) – Seikagaku
10.16 Drugs In Phase 2 Development For Dry Eye
10.16.1 ESBA105 (TNF-alpha antibody) – Alcon (Novartis)
10.16.2 Kineret (anakinra: IL-1 receptor antagonist) – Amgen/Sobi
10.17 Other Drugs In The Development Pipeline For Ophthalmic Conditions
10.17.1 Brimonidine For Eye Whitening – Valeant
10.17.2 GS-101 (aganirsen) – Gene Signal
10.17.3 Omidria (phenylephrine/ketorolac) – Omeros
11. Qualitative Analysis Of The Ophthalmic Drugs Market, 2016-2026
11.1 Market Factors Influencing Ophthalmic Drugs
11.2 SWOT Analysis Of The Global Ophthalmic Drugs Market, 2016-2026
11.3 Strengths
11.3.1 A Healthy R&D Pipeline
11.3.2 Advances In Drug Delivery Technologies
11.3.3 Support For Reimbursement And Payment Approvals
11.3.4 Gene Therapy And RNAi Technology
11.3.5 New Ophthalmic Therapeutic Applications For Drugs
11.3.6 Development Of Neuroprotective Anti-Glaucoma Medications
11.3.7 Biomarkers As Tools For Better Diagnosis And Treatment
11.4 Weaknesses
11.4.1 Low Levels of Patient Adherence To Treatment
11.4.2 High Treatment Burden On Patients And Healthcare Providers
11.4.3 Under-Diagnosis And Under-Treatment
11.5 Opportunities
11.5.1 Sustained-Release Ocular Implants
11.5.2 The Impact Of A Rapidly Ageing Global Population
11.5.3 Increasing Prevalence of Diabetes and Ocular Disease
11.5.4 Glaucoma And Retinal Disorders Set for Most-Marked Increases in Prevalence
11.5.5 Unmet Clinical Need In Many Disease Areas
11.5.6 Economic Growth In Emerging Market Provide Opportunity For Expansion
11.6 Threats
11.6.1 Intensifying Price Regulation In The Market
11.6.2 Generic Competition – Likely to Cause Erosion of Sales for Market Leading Brands
11.6.3 Rising Cost Of R&D
11.6.4 Biosimilars – A Bigger Threat than Generics?
11.7 Porter’s Five Force Analysis Of The Global Ophthalmic Drugs Market, 2016-2026
11.7.1 Threat of New Entrants
11.7.2 Rivalry Among Competitors
11.7.3 Power of Suppliers
11.7.4 Threat of Substitutes
11.7.5 Power of Buyers
12. Conclusions
12.1 Overview Of Current Market Conditions And Market Forecast, 2015-2026
12.2 Leading Sectors In Ophthalmic Drugs In 2015
12.3 Leading Regions In The Ophthalmic Drugs Market In 2015
12.4 Leading Companies In The Ophthalmic Drugs Market, 2015
12.5 What Does The Future Hold For Ophthalmic Drugs?
13. Glossary
【レポート販売概要】
■ タイトル：眼薬の世界市場予測2016-2026■ 英文：Ophthalmic Drugs Market Forecast 2016-2026
■ 発行日：2016年7月
■ 調査会社：visiongain
■ 商品コード：VGAIN81924
■ 調査対象地域：グローバル
- 前立腺生検の世界市場2017-2021：針生検、液体生検About Prostate Biopsy Market Biopsy is a clinical procedure primarily used in the detection and extraction of malignant or cancerous cells and their abnormal growth in the body for further analysis and interpretation of diseases. The purpose of removing tissues or cells during the procedure is mainly to limit the spread of tumor, minimize morbidity, and eliminate interference with future treatment …
- チアクロプリドの世界市場2015Thiacloprid (CAS 111988-49-9) Market Research Report 2015 aims at providing comprehensive data on Thiacloprid market globally and regionally (Europe, Asia, North America, Latin America etc.) The report includes Thiacloprid description, covers its application areas, manufacturing methods, patterns. It captures Thiacloprid market trends, pays close attention to Thiacloprid manufacturers and names su …
- 遊園地の世界市場2017-2021About Amusement Parks Amusement parks attract and entertain individuals through a variety of adventure games such as water and dry rides. Amusement parks charge customers a pre-defined fee for delivering these services. They contribute immensely to the world GDP and employment. Amusement parks generate revenue through many streams such as tickets, hospitality, merchandizing, licensing, and events. …
- Ultra Petroleum Corp.社の石油・ガス開発・生産動向及びコスト分析（2013年）Ultra Petroleum Corp. Oil & Gas Exploration and Production Operations and Cost Analysis - 2013 Summary Ultra Petroleum Corp. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for …
- バイタルサインモニタリング装置の世界市場：体温、血圧、パルスオキシメーターAbout Vital Signs Monitoring Devices Vital sign monitors are used to measure body temperature, heart rate, respiration rate, and blood pressure. Vital signs can be measured, monitored, and observed with the use of several diagnostic devices. These devices have applications in both fitness monitoring and medical diagnostics. It also provides information related to abnormalities of a patient to medi …
- P2P融資の世界市場2016-2020About P2P lending It is a method of debt financing where different individuals can lend and borrow money using an online platform, which eliminates any involvement of middlemen. The loans provided by the lender helps the lender to generate income in the form of interest. On the other hand, the borrowers have easy access to financing, which might be difficult for them to procure if they approach a …
- 構造ヘルスモニタリング（SHM）の世界市場Structural health monitoring (SHM) is a system that provides in-time and accurate information regarding performance and condition of structures. Information from SHM systems aid in planning and designing maintenance activity, thereby increase safety, reduce uncertainty, and lower operating expenses. The Structural health monitoring market report covers the application segment such as bridges, dams …
- ストリーミング分析の世界市場予測（～2024年）The global streaming analytics market size to grow at a CAGR of 28.2% during the forecast periodThe streaming analytics market size is expected to grow from USD 10.3 billion in 2019 to USD 35.5 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 28.2% during the forecast period. The streaming analytics market is driven by various emerging technologies, such as big data, Internet of Things …
- 内皮機能障害：治療薬のグローバル治験動向（2014年下半期）Endothelial Dysfunction Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Endothelial Dysfunction Global Clinical Trials Review, H2, 2014" provides data on the Endothelial Dysfunction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Endothelial Dysfunction. It includes an overview of the trial numbers …
- グローバル太陽光発電市場動向The use of renewable energy is no longer an out of the ordinary concept. Photovoltaics and solar power are a major resource of producing energy today. In fact, it is estimated that in 2010, solar photovoltaics was used for generating electricity in over 100 countries around the world. However, while it was used in so many countries, the overall percentage of solar photovoltaics only amounted to 4. …
- 高性能ポリアミドの世界市場展望2017-2026According to Stratistics MRC, the Global High-Performance Polyamides market is accounted for $1.84 billion in 2017 and is expected to reach $3.77 billion by 2026 growing at a CAGR of 8.3% during the forecast period. Some of the key factors such as an increase in demand for high-performance polyamides in the medical industry and growing importance on weight diminution in the automotive sector are d …
- 産業ロボット用センサーの世界市場2017-2021ABSTRACTAbout Industrial Robot Sensors Robot sensors are devices that detect and measure changes in the internal and external environment of a robot. The information collected by robot sensors are then sent in the form of signals to the controller of the robot, which in turn helps in ensuring a smooth operation of the robot. Vendors in the global industrial robots market are expected to have a bur …
- 小動物向け画像診断機器（イン・ビトロ）の世界市場予測（～2021年）：光学イメージング、PET、SPECT、CT、MRI、超音波、光音響画像化装置、磁気粒子画像装置The global small animal imaging market is expected to reach a value of USD 910.4 Million by 2021; growing at a CAGR of 6.2% during 2016-2021. A number of factors such as technological advancements in the field of molecular imaging, increasing market demand for non-invasive small animal imaging techniques, and growing number of public-private initiatives and funding to support preclinical researche …
- 1型糖尿病治療薬の世界市場予測および分析PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 Summary Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously, as at present, no other treatment can be offered to a patient who is newly …
- セーフティレーザースキャナーの世界市場予測（～2023年）“SAFETY LASER SCANNER MARKET TO GROW AT A HIGHER CAGR of 5.99% DURING 2018–2023”The overall safety laser scanner market is expected to grow from USD 304 million in 2018 to USD 406 million by 2023, at a high CAGR during the forecast period. Safety laser scanners offer long-term cost-effective solutions for use with new machine installations or for retrofitting machines, plants, or even vehicles. Th …
